

Applicants have amended claims 115, 127 and 132 in order to more clearly describe their invention. Support for the recitation.

In the prosecution of the parent of the present application (U.S. Patent Application Serial No. 09/144,838) the Examiner had rejected claims 28-36 pursuant to 35 USC §112 first paragraph out of a concern that the originally filed specification fails to establish that the invention of a cross-over protein that contains at least one peptide segment whose sequence is derived from one parent protein and at least one peptide segment whose sequence is derived from a second parent protein is not described in the specification in such a way as to reasonably convey to those of ordinary skill in the art that the inventors had possession of this invention at the time of the filing of the patent application.

Applicants respectfully submit that the originally filed application clearly evidences their possession of the above-mentioned aspect of the present invention. In this regard, the application states:

- “Novel proteins comprising a combination of two or more functional modules from two or more different parent proteins ... are provided.” [page 5, lines 12-14]
- “The present invention provides cross-over proteins produced by chemical ligation of two or more functional protein modules derived from two or more different parent protein modules.” [page 8, lines 2-4]
- “As can be appreciated, any number of modular combinations and ligation orders are possible.” [page 11, lines 9-10]
- “Of particular interest are cross-over protein molecules synthesized by combining a functional module from a first protein with a functional module from a second

protein. Additional functional modules can be combined from the same and/or one or more other proteins.” [page 12, line 32 – page 13, line 2]

Applicants respectfully submit that the ability to combine modules from the same or different proteins is clearly enabled by the present application, which teaches how to identify functional modules (see Example 1, page 34), and how to produce cross-over proteins containing 4 such modules (see Examples 2-5). The present application clearly evidences that the inventors were in possession of this attribute of the present invention, and that it is described in terms sufficient to enable its practice by those of ordinary skill.

In the prosecution of the parent of the present application (U.S. Patent Application Serial No. 09/144,838) the Examiner had rejected claims 28-36 as indefinite pursuant 35 USC § 112, second paragraph. Specifically, the Examiner had advised that the use of the terms “first” and “second” to provide antecedent basis to the molecules recited in the claims renders the claims indefinite. Additionally, the Examiner expressed concern that the term “parent” protein rendered the claims indefinite to those of ordinary skill.

Applicants have amended the claims in order to more clearly describe the antecedent basis for the terms “first” and “second;” and have deleted the term “parent” from the claims.

In the prosecution of the parent of the present application (U.S. Patent Application Serial No. 09/144,838) the Examiner had additionally rejected the preamble of claim 28 as “being more appropriate for a library than a single protein” (citing the preamble of Applicants’ claim 32). The preamble of claim 32 recites a library of *members* and then proceeds to recite a characteristic of the *members*. Accordingly, there is believed to be no inconsistency in the usage of the recite characteristics.

In the prosecution of the parent of the present application (U.S. Patent Application Serial No. 09/144,838) the Examiner had additionally rejected the claims as containing “redundant” or

“inherent” terminology. Applicants respectfully submit that inclusion of recitations of certain features permits the claims to provide proper antecedent basis for terms used in dependent claims. Applicants respectfully submit that the inclusion of recitations (even if “redundant” or “inherent”) does not render a claim indefinite.

In the prosecution of the parent of the present application (U.S. Patent Application Serial No. 09/144,838) the Examiner had additionally rejected the claims in light of their recitation that the molecules have “a C-terminus and an N-terminus.” The rejection is stated to reflect a concern that due to such recitation “it is unclear whether the cross-over proteins now contains at the ‘left’ side of the peptide sequence as the C-terminus and the ‘right’ side as the N-terminus.”

Applicants submit that molecules do not have a “left” and “right” portion, and accordingly are not properly referred to using directional aids. Referring to their sequences in terms of their chemistry is believed to be both proper and preferred.

The Examiner of the parent application had rejected the claims pursuant to 35 USC §102(b) in light of Canne *et al.* (J. Am. Soc.), Dawson *et al.*, Clark-Lewis *et al.* (J. Biol. Chem.) or Gaertner *et al.*, each applied singly.

Regarding the Canne *et al.* reference, the Examiner drew Applicants’ attention to page 3002, col. 2, which recites that:

“...the peptide segments 1 and 3 contained a carboxy-terminal-Leu-COSH ... the resulting ligations between these peptides and the amino terminal bromoacetyl groups of the segments 2 and 4 gave a –Leu[COS]Gly-sequence at the site of ligation ... condensation of 32-residue COSH segment and a 53-residue bromoacetylated gave an 86-residue product.”

Applicants respectfully invite the Examiner to review the cited passage of this reference. It is submitted that segments 1 and 2 are domains of the one protein (cMyc) and that segments 3 and 4 are domains of a second protein (Max). The ligations of segment 1 to 2 or of segment 3 to

4 is thus not the ligation of peptides of different proteins, and as such is irrelevant to the claimed invention, which concerns an $-\text{[N—C]} - \text{[N—C]}-$ linkage of peptides from different proteins.

While the Canne *et al.* reference does also teach the ligation of peptides from different proteins (i.e., the [1-2 cMyc molecule] and the [3-4 Max molecule]), the reference clearly teaches that the [1-2 cMyc molecule] and the [3-4 Max molecule] are ligated in an ***C-terminal to C-terminal ligation*** (i.e., $[\text{N—C}] - [\text{C—N}]$) (see page 2999, first sentence of paragraph bridging left and right columns), and that the resulting ligation product thus possesses **two N-termini and no C-terminus**.

Regarding the Dawson *et al.* reference, the Examiner had drawn Applicants' attention to Figure 2 as disclosing the ligation of "two different segments." The Examiner had further drawn Applicants' attention to note 4 at page 778 of the Dawson *et al.* document. This note discloses the ligation of two pentapeptides.

Applicants respectfully submit that their invention relates not merely to the ligation of different peptide segments, but to the ligation of **functional domains** of different peptide segments **of different proteins**. The ligation discussed in Figure 2 of the Dawson *et al.* document involves two segments of the same protein (IL-8). The ligation discussed in note 4 involves two pentapeptides. No function or origin is disclosed to be associated with either peptide.

Regarding the Gaertner *et al.* reference, the Examiner drew Applicants' attention to the statement that "... a new approach for linking, through a thioether bond, the C-terminus of one unprotected polypeptide with the N-terminus of another" and has professed that such recitation establishes that "two different segments from two different polypeptides are used."

Applicants respectfully submit that the Gaertner *et al.* reference is clear in stating that the "two different polypeptides" used are two polypeptide fragments of the same protein that are to

be religated together (see the title: Site-Specific Religation of G-CSF Fragments through a Thioether Bond”). Applicants submit that the reference fails to teach the recitations needed to anticipate Applicants’ invention of a ***method*** of producing a cross-over protein, in which:

- (1) functional domains
- (2) of different peptide segments
- (3) of different proteins
- (4) are ligated to one another.

Regarding the Clark-Lewis *et al.* reference, the Examiner drew Applicants’ attention to the statement that “hybrids between IL-8 and the inactive IP10 protein were designed to identify structural regions and residues required for IL-8 activity.” Applicants respectfully submit that the basis of the Examiner’s rejection is unclear since the reference does not teach the **ligation** of *any* peptides, but rather the chemical synthesis of an intact protein. Thus, it is irrelevant that IL-8 and IP10 are different. The present invention, as stated above, relates to the **ligation** of functional domains of different peptide segments of different proteins.

The Examiner of the parent application had rejected claims 32-34 and 36 pursuant to 35 USC § 102(b) in light of Cwirla *et al.* Applicants respectfully submit that the pending claims are directed to methods and not compositions of matter. Prior art is thus relevant to the patentability of the pending claims only if it discloses or suggests the method being claimed. In this light, Applicants respectfully submit that the present invention relates to the **ligation** of functional domains of different peptide segments of different proteins. The fusion proteins produced by Cwirla *et al.* are simply **not** produced through such a method. Indeed, they are formed through a completely different process: the process of *in vivo* protein translation.

The Examiner of the parent application had rejected claims 28-36 pursuant to 35 USC § 102(b) in light of Stricht *et al.* Applicants draw the Examiner’s attention to the language of the present method claims, which recite a process of forming cross-over proteins through the **ligation** of functional domains of different peptide segments of different proteins. That method is not

taught or suggested by the Stricht *et al.* document. As is evident, the Stricht *et al.* document concerns a recombinant process in which proteins are produced through **translation**. As such, Applicants submit that the reference does not disclose the production of a “cross-over protein library” nor the formation of any protein through the act of ligation of functional domains of different peptide segments of different proteins as recited in the claims presented for examination.

The Examiner has provisionally rejected claims 28-31 under the judicially created doctrine of obviousness-type double patenting in light of claims 1-6 of co-pending Application Serial No. 08/945,997 or over claims of co-pending Application Serial No. 09/097,094.

Applicants respectfully submit that the presently claimed invention is not an “obvious variant” of those claimed in the above-cited applications. As Applicants have previously stated, one looks to the claims of two applications rather than to their disclosures in order to assess the propriety of a double-patenting rejection. *Panduit Corp. v. Dennison Mfg. Co.*, 227 USPQ 337 (Fed. Cir. 1985).

A comparison of claim 28 of the present application and claim 1 of the ‘997 application, shows that the inventions of these applications are drawn to substantially dissimilar and clearly patentably distinct inventions. The claims of these inventions possess very different attributes:

<u>Attribute</u>	
Claim 28 of the Present Invention	Claim 1 of the ‘997 Application
1. Sequence of each oligopeptide must be derived from two different proteins	1. Sequence of each oligopeptide need <u>not</u> be derived from two different proteins
2. Each peptide must comprise a functional protein module	2. Each peptide need <u>not</u> comprise a functional protein module
3. No requirement that one oligopeptide possess a C-terminal thioester	3. One oligopeptide must possess a C-terminal thioester

4. No requirement that one oligopeptide possess a C-terminal thioester	4. One oligopeptide must possess an N-terminal cysteine
5. No requirement that any peptide have an unoxidized sulfhydryl side chain	5. The N-terminal cysteine must have an unoxidized sulfhydryl side chain
6. No requirement for the formation of a β -aminothioester bond between the two peptides;	6. Requires the formation of a β -aminothioester bond between the two peptides;
7. No requirement for the presence of a catalytic thiol	7. Requires the presence of a catalytic thiol
8. No requirement for the linking of the peptides via an amide bond	8. Requires the linking of the peptides via an amide bond

Applicants submit that an obviousness-type double patenting rejection is not appropriate in the present circumstance since the present application and Application Serial No. 08/945,997 do not claim the same or similar inventions and hence do not reflect an improper timewise extension of the right to exclude.

Applicants respectfully submit that an obviousness-type double patenting rejection is likewise inappropriate since the present application and Application Serial No. 09/097,094 do not claim the same or similar inventions and hence do not reflect an improper timewise extension of the right to exclude.

A comparison of claim 28 of the present application and claim 1 of the '094 application, shows that the inventions of these applications are likewise drawn to substantially dissimilar and clearly patentably distinct inventions that possess very different attributes:

<u>Attribute</u>	
Claim 28 of the Present Invention	Claim 1 of the '094 Application
1. Sequence of each oligopeptide	1. Sequence of each oligopeptide need

must be derived from two different proteins	<u>not</u> be derived from two different proteins
2. Each peptide must comprise a functional protein module	2. Each peptide need <u>not</u> comprise a functional protein module
3. No requirement that one oligopeptide possess a C-terminal thioester	3. One oligopeptide must possess a C-terminal thioester
4. No requirement that one oligopeptide possess a C-terminal thioester	4. One oligopeptide must possess an N-terminal cysteine
5. No requirement that any peptide be bound to a solid phase	5. At least one peptide must be bound to a solid phase before and after ligation
6. No requirement for a cleavable or uncleavable linker	6. The peptide that is bound to a solid support must be bound through a cleavable linker
7. No requirement that the N-terminus of the ligated peptide be bound to a solid phase	7. The N-terminus of the ligated peptide is bound to a solid phase
8. No requirement for the linking of the peptides via an amide bond	8. Requires the linking of the peptides via an amide bond

Applicants respectfully submit that in light of such numerous and distinct claim limitation differences, the issuance of both the '094 application and the claims of the present application would not serve to improperly extend the "right to exclude."

For example, the method to the present application could be conducted using any of oxime forming chemical ligation, thioester forming ligation, thioether forming ligation, hydrazone forming ligation, thiazolidine forming ligation, and oxazolidine forming ligation, without in any way extending the "right to exclude" provided by the '094 application, since the claims of that application concern the use of native chemical ligation.

Conversely, the method of claim 1 of the '094 application could be practiced using peptide segments that did not comprise functional protein modules of pre-existing proteins without an anyway extending the "right to exclude" that would be provided by the present application upon its issuance. Applicants respectfully submit that the presently pending claims define a patentable distinct invention over the invention of the claims of the '094 application. in


The Examiner has provisionally rejected claims 28-31 as obvious pursuant to 35 USC §103(a) in light of co-pending Applications Serial Nos. 08/945,997 or 09/097,094. Applicants respectfully submit that this rejection is not applicable to the claims of this Continuing Patent Application.

Applicants have respectfully submit that if no fee is required for consideration of this submission beyond those accompanying this submission. Should that determination be incorrect, then please debit account 50-0548, and notify Applicants.

Applicants respectfully submit that the present application is in condition for Examination and earnestly solicit early notice of favorable action. Should the Examiner believe additional discussion would advance the prosecution of the present application, he is invited to contact the undersigned at the local telephone number listed below.

Date: 8/13/2001
Liniak, Berenato, Longacre & White, LLC
6550 Rock Spring Drive, Suite 240
Bethesda, MD 20817
Telephone: (301) 896-0600
Facsimile: (301) 896-0607


Respectfully Submitted,



Jeffrey I. Auerbach
Reg. No. 32,680
Attorney for Assignee

Appendix A

In re CPA Application of Siani, et al.
Serial No. of Prior Application: 09/144,838
Atty Dkt. No.: GRFN-20/01US



Appendix A: The Nature of the Amendments

To facilitate the Examiner's review of the of the patentability of the present invention, Applicants have reproduced below the nature of the amendments to the claims and specification:

Amendments to the Claims:

28. **[Twice Amended]** A method of producing a cross-over protein that contains at least one peptide segment whose sequence is derived from [one parent] **a first** protein and at least one peptide segment whose sequence is derived from a second [parent] protein, said method comprising:

ligating under chemoselective chemical ligation conditions (i) at least one N-terminal peptide segment comprising a functional protein module derived from said first [parent] protein, and (ii) at least one C-terminal peptide segment comprising a functional protein module derived from said second [parent] protein having an amino acid sequence that is different from said first parent protein, wherein said N-terminal peptide segment and said C-terminal peptide segment comprise compatible reactive groups capable of chemoselective chemical ligation to one another, whereby a covalent bond is formed between said compatible reactive groups of said N-terminal peptide segment and said C-terminal peptide segment so as to produce a chemical ligation product comprising a cross-over protein having a C-terminus and an N-terminus.

30. **[Twice Amended]** The method of claim 28, wherein the first and second [parent] protein molecules from whose sequences said N-terminal peptide(s) and said C-terminal peptide(s) are derived belong to the same family of protein molecules.
31. **[Amended]** The method of claim 28, wherein said chemoselective chemical ligation is selected from the group consisting of native chemical ligation, oxime forming chemical

Appendix B

In re CPA Application of: **Siani, M.A. *et al.***
Serial No. of Prior Application: **09/144,838**
Atty Dkt. No.: GRFN-20/01US

Preliminary Amendment

Page 2

ligation, thioester forming ligation, thioether forming ligation, hydrazone forming ligation, [thiazolidine] **thiazolidine** forming ligation, and oxazolidine forming ligation.

32. **[Twice Amended]** A method of producing a cross-over protein library whose members contain at least one peptide segment whose sequence is derived from [one parent] **a first** protein and at least one peptide segment whose sequence is derived from a second [parent] protein, said method comprising:

ligating under chemoselective reaction conditions a plurality of unique N-terminal peptide segments each comprising one or more functional protein modules derived from said first [parent] protein and a plurality of unique C-terminal peptide segments each comprising one or more functional protein modules derived from a second [parent] protein having an amino acid sequence that is different from said first [parent] protein, wherein said N-terminal peptide segments and said C-terminal peptide segments comprise compatible reactive groups capable of chemoselective chemical ligation to one another, whereby a covalent bond is formed between said compatible reactive groups of said N-terminal peptide segments and said C-terminal peptide segments so as to produce a plurality of chemical ligation products comprising a plurality of unique cross-over proteins each having a C-terminus and an N-terminus.

33. **[Amended]** The method of claim 32, wherein said plurality of N-terminal peptide segments are obtained by cross-over ligation of two or more different [parent] **families of** protein molecules.
34. **[Amended]** The method of claim 32, wherein said plurality of C-terminal peptide segments are obtained by cross-over ligation of two or more different [parent] **families of** protein molecules.

Appendix B

In re CPA Application of: **Siani, M.A. *et al.***
Serial No. of Prior Application: **09/144,838**
Atty Dkt. No.: GRFN-20/01US

Preliminary Amendment

Page 3

35. **[Twice Amended]** The method of claim 32, wherein the first and second **[parent]** protein molecules from whose sequences said N-terminal peptide(s) and said C-terminal peptide(s) are derived belong to the same family of protein molecules.

Amendments to the Specification:

The paragraph beginning at page 19, line 25 and continuing to page 20, line 9 has been amended as follows:

-- Assays of particular interest employ receptors provided by tissues or cell preparations, synthetic preparations and the like. Receptors of particular interest are lipid membrane-bound receptors generated by lipid matrix-assisted chemoselective chemical ligation as described in **[co-pending application U.S. Serial No. [to be assigned] filed August 31, 1998 (Attorney Docket No. GRFN-O28/00US)] U.S. Patent Application Serial No. 144,964**. Screening for binding of a cross-over protein ligand comprising one or more chromophores to a target receptor is preferably performed in a FRET assay. Ligand binding can be measured by any number of methods known in the art for FRET analyses, including steady state and time-resolved fluorescence by monitoring the change in fluorescence intensity, emission energy and/or anisotropy, for example, through energy transfer from a donor moiety to an acceptor moiety of the FRET system. (See, e.g., Wu et al., *Analytical Biochem.* (1994) 218: 1-13). FRET assays allow not only distance measurements, but also resolution of the range of donor- to-acceptor distances. FRET also can be used to show that the ligand and/or target receptor exists alternately in a single conformational state, or with a range of donor-to-acceptor distances when in a different state, such as when bound to a ligand. More than one donor-acceptor pairing may also be included.